secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mineralys Therapeutics, Inc. (MLYS)
CIK:        0001933414
Form:       8-K
Filed at:   2025-02-04T23:59:59+00:00
Accession:  0001933414-25-000006
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mineralys completes enrollment in Explore-CKD Phase 2 trial of lorundrostat; topline data expected Q2 2025
--------------------------------------------------------------------------------

- Phase 2 trial evaluating lorundrostat for hypertension in Stage 2-3b CKD with albuminuria on stable ACEi/ARB and SGLT2i.
- Primary endpoint: change from baseline in systolic BP at week 4 vs placebo; exploratory endpoint includes UACR change.
- Third trial to recently complete enrollment, alongside Target-HTN, Advance-HTN, and Explore-OSA.
- Topline data anticipated in Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933414/000193341425000006/0001933414-25-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933414/000193341425000006/mlys-20250204.htm
  HTML page:      https://secwatch.observer/filing/0001933414-25-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer